Trial · NCT04812925
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 28 of 28
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Pharmacodynamics markers: total IgG | Up to 52 weeks | |
| Secondary | Percentage of participants who performed self-administration at home over time | Up to 52 weeks | |
| Secondary | Percentage of caregivers who administered the injection to the patient at home over time | Up to 52 weeks | |
| Secondary | Number of training visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC | Up to 52 weeks | |
| Secondary | Percentage of self- or caregiver-supported administrations at home | Up to 52 weeks | |
| Secondary | Incidence of antibodies to efgartigimod | Up to 216 weeks | |
| Secondary | Titers of antibodies to efgartigimod | Up to 216 weeks | |
| Secondary | Presence of NAb against efgartigimod | Up to 216 weeks | NAb : Neutralizing antibodies |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04812925/registered?page=2